GlassScriptPhysician profile
Scott A Martin
NPI 1639154040
$2,596.45
in general payments reported to CMS, 2019-2025
22 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,038 · 2022: $810 · 2023: $392 · 2024: $203 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $748.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $572.92 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $339.63 | 2021-2025 | Jardiance |
| Abbvie INC. | $327.95 | 2021-2023 | |
| Amgen INC. | $143.02 | 2021-2022 | |
| Astellas Pharma US INC | $138.56 | 2021-2024 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $136.90 | 2021-2024 | Farxiga, Breztri |
| Sanofi-Aventis U.S. LLC | $121.72 | 2021-2022 | |
| Glaxosmithkline, LLC. | $121.02 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $96.57 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.98 | 2021-2024 | Xifaxan |
| Exact Sciences Corporation | $90.05 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $70.06 | 2021-2022 | |
| Pfizer INC. | $60.52 | 2023-2024 | |
| Esperion Therapeutics, INC. | $57.34 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $43.82 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $41.24 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $40.16 | 2022 | |
| Arbor Pharmaceuticals, INC. | $28.67 | 2021 | |
| Phathom Pharmaceuticals, INC. | $22.53 | 2024 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $18.32 | 2021 | |
| Amarin Pharma, INC. | $17.30 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.